Immune thrombocytopenia (ITP): vizsgálatok itt: Kína
67 trials · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.
- Korai 1. fázisTaking peopleAn Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 20
- Run by
- Shanghai Cell Therapy Group Co.,Ltd
See details and how to joinNCT07174843 - 1/2. fázisTaking peopleA Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
- Where
- Guangzhou, Jinan, Tianjin, Wuhan
- Életkor
- 18 év to 64 év
- People
- 68 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06721013 · EU 2024-518502-40-00 - 3. fázisTaking peopleA Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Where
- Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou
- Életkor
- 18 év and over
- People
- 171 worldwide
- Run by
- Takeda
See details and how to joinNCT06722235 · EU 2024-514401-54-00 - 3. fázisTaking peopleA Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Where
- Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- Takeda
See details and how to joinNCT06948318 · EU 2025-521692-31-00 - No phaseNot yet taking people in KínaClinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
- Where
- Nanchang
- Életkor
- 18 év to 65 év
- People
- 24
- Run by
- Nanjing Miracle Biotechnology Co., Ltd.
See details and how to joinNCT07811622 - 2. fázisTaking peopleSG301-SC Injection Safety Study in Subjects With Primary ITP Patients
- Where
- Baoding, Changzhi, Chengde, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Jining, Kunming, Liuzhou, Pingdingshan, Siping, Tangshan, Tianjin, Wenzhou, Wuhan, Xian, Xiangyang, Yulin, Zhenzhou
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Hangzhou Sumgen Biotech Co., Ltd.
See details and how to joinNCT07710248 - 4. fázisTaking peopleMulti-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 38
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07788456 - 1/2. fázisTaking peopleA Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
- Where
- Beijing, Bengbu, Nanchang, Tangshan, Tianjin, Xi’an, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 56
- Run by
- Jiangsu BioJeTay Biotechnology Co., Ltd.
See details and how to joinNCT06929299 - 2. fázisNot yet taking people in KínaEltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
- Where
- Tianjin
- Életkor
- 18 év to 80 év
- People
- 40
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07687134 - No phaseNot yet taking people in KínaAtorvastatin Combined With NAC Plus Romiplostim for Management of ITP
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 50
- Run by
- Peking University People's Hospital
See details and how to joinNCT07662525 - 2/3. fázisTaking peopleSirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 164
- Run by
- Chinese SLE Treatment And Research Group
See details and how to joinNCT07657793 - 1. fázisTaking peopleRN1201 Injection in the Treatment of Antibody-Mediated Diseases
- Where
- Suzhou
- Életkor
- 16 év to 65 év
- People
- 9
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07072247 - 1. fázisTaking peopleIASO-782 in Autoimmune Hematological Diseases
- Where
- Tianjin, Wuhan
- Életkor
- 18 év to 65 év
- People
- 16
- Run by
- Shanghai IASO Biotechnology Co., Ltd
See details and how to joinNCT06534021 - 1. fázisTaking peoplePhase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 10
- Run by
- Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07206758 - No phaseTaking peopleRomiplostim for Oral TPO-RA Resistant ITP
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 60
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07612319 - 1. fázisNot yet taking people in KínaUniversal STAR-T Cell Injection in R/R Autoimmune Diseases.
- Where
- Haidian
- Életkor
- 18 év to 65 év
- People
- 6
- Run by
- Jian Zhu
See details and how to joinNCT07599280 - 3. fázisNot yet taking people in KínaATRA for Management of Primary ITP
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 192
- Run by
- Peking University People's Hospital
See details and how to joinNCT07597395 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
- Where
- Beijing, Bengbu, Chengde, Hohhot, Huai'an, Huizhou, Tianjin, Wuhan, Wuxi, Zhenjiang
- Életkor
- 18 év and over
- People
- 69 worldwide
- Run by
- argenx
See details and how to joinNCT06544499 · EU 2024-515451-38-00 - 3. fázisTaking peopleHigh-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia
- Where
- Jinan
- Életkor
- 18 év to 80 év
- People
- 86
- Run by
- Shandong University
See details and how to joinNCT07559331 - 4. fázisTaking peopleEltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
- Where
- Tianjin
- Életkor
- 18 év to 60 év
- People
- 224
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT04518475 - Korai 1. fázisTaking peopleUCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 27
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07441525 - Korai 1. fázisNot yet taking people in KínaA Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 27
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07416032 - No phaseTaking peopleLongitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
- Where
- Tianjin
- Életkor
- 6 év to 17 év
- People
- 500
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06107582 - 2. fázisTaking peopleRituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 160
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07234019 - 2. fázisTaking peopleAnti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 160
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07297563